3 months ago
10
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025.
| TD Cowen 45th Annual Health Care Conference | |
| Date: | March 5, 2025 |
| Time: | 9:50 AM EST |
| Location: | Boston, MA |
| Format: | Corporate Presentation |
| Presenter: | Alise Reicin, MD, President and Chief Executive Officer |
| Webcast: | Link |
| Leerink Partners Global Healthcare Conference | |
| Date: | March 11, 2025 |
| Time: | 11:20 AM EDT |
| Location: | Miami, FL |
| Format: | Fireside Chat |
| Presenters: | Daniel Lochner, Chief Financial Officer, and Marc Schwabish, PhD, Chief Business Officer |
| Webcast: | Link |
Both live webcasts can also be accessed under "Events & Presentations” on the Investors section of the Tectonic website at www.tectonictx.com. Once these conferences have concluded, a replay of the two webcasts will be available on the Company's website for approximately 90 days.
The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink representative to schedule meetings.
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
About Tectonic
Tectonic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs”). Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow on LinkedIn.
CONTACT: Contacts:
Investors:
Dan Ferry
LifeSci Advisors
(617) 430-7576
Media:
Kathryn Morris
The Yates Network
(914) 204-6412
